52-week range
Price risk
Balance sheet & cash
Was the rally earned?
Mostly yes.
- Per-share earnings added 57 points to the rise, while the multiple moved less (P/E 52.3x to 55.4x).
- The share count rose 35%.
What do "pts" mean?
"pts" are percentage points of the share price return. The parts add up to the total shown for each period. Because price = P/E × net profit ÷ share count, higher profit pushes the price up, a higher P/E pushes it up, and more shares push it down.
Example: if the price rose 34% and profit growth accounts for +58 pts while a lower P/E accounts for -24 pts, then 58 - 24 = 34. The +58 is not the profit growth rate itself: it is the part of the price move that profit growth explains.
Not shown for 3 years and 5 years: earnings were negative at one end, or there is not enough history.
Net profit is trailing twelve months as reported with a 60-day lag.
What is the price implying?
At a P/E of 55.4x, the price would imply about 27.6%/yr earnings growth for 10 years under the same assumptions, but it is not ranked.
Fewer than six years of annual earnings are available, which is too little to measure delivered growth.
“Implied growth” is what the current price would require under our stated assumptions, not what we expect.
What prices imply across Health Technology The market-wide Expectations lists
What changed?
- Sep '26Debt / equity halved over 12 months to 0.26x.
- Sep '26Share count is up 38.5% over 12 months.
- Aug '26Volume reached 18.4x its 50-day median on 2026-08-31; price +1.4% that day.
- Jun '26Volume reached 6.6x its 50-day median on 2026-06-04; price +6.1% that day.
- Apr '26Regained the 2026-01 peak, 1 month after the low.
- Mar '26Fell 36% from the Jan 2026 peak to the Mar 2026 low.
- Feb '26Volume reached 16.0x its 50-day median on 2026-02-11; price -4.1% that day.
- Dec '25Volume reached 8.2x its 50-day median on 2025-12-29; price +3.5% that day.
Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.
Where price and fundamentals disagree, market-wide Rewind the whole market to any month
Are profits backed by cash?
1 of 1 checks are within range.
Tap a check to see how it is measured.
Other income reliance2%Within range
Other income as a share of pre-tax profit (trailing twelve months): 2.1%. Bands: below 15%, 15% to 35%, above 35%.
Tax rate—Not enough data
Not enough reported data to compute this.
Cash conversion—Not enough data
Not enough reported data to compute this.
Free cash flow—Not enough data
Not enough reported data to compute this.
Receivable days vs history—Not enough data
Not enough reported data to compute this.
Capital work in progress—Not enough data
Not enough reported data to compute this.
Payable days—Not enough data
Not enough reported data to compute this.
How to read this
Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.
How rough has the ride been?
Monthly share price
Last 90 trading days
Drawdown from peak
Largest drawdowns
-36.4% (2026-01 peak to 2026-03 low, recovered 2026-04)
-22.5% (2026-04 peak to 2026-05 low, recovered 2026-06)
-20.5% (2026-06 peak to 2026-10 low, not yet recovered)
Most recent volume spikes
2026-08-31: 18.4x the 50-day median, price +1.4% that day
Where does it rank among Health Technology peers?
Each cell is the company's percentile rank among its Health Technology peers (non-financial companies) that month.
Darker is better-ranked.
Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).
Percentiles use today's listed companies in the sector and need at least 5 peers with a value; grey cells have too few.
ROE is computed from net profit and book value where the source does not report it.
The Health Technology sector page Watch it move against Health Technology in the Observatory
What else looks like this?
Companies with the most similar financial profile today, regardless of industry.
| Company | Sector | Similarity | Closest on |
|---|---|---|---|
| AIMTRON ELECTRONICS (AIMTRON) | Electronic Technology | 60% | debt/equity, revenue |
| OBSC PERFECTION (OBSCP) | Producer Manufacturing | 59% | market cap, volatility |
| PRIZOR VIZTECH (PRIZOR) | Electronic Technology | 55% | revenue, ROCE |
| PARTH ELECTRICALS AND ENG (PARTH) | Producer Manufacturing | 54% | promoter holding, revenue |
| KRISHNA DEFENCE AND ALLIED (KRISHNADEF) | Electronic Technology | 44% | market cap, revenue |
| ANLON HEALTHCARE (AHCL) | Health Technology | 58% | revenue, volatility |
| BETA DRUGS (BETA) | Health Technology | 42% | market cap, promoter holding |
| SAKAR HEALTHCARE (SAKAR) | Health Technology | 21% | P/E, market cap |
Similarity is statistical, based on reported metrics; it does not imply similar business quality or future returns.
What happened next to similar setups
- We found 50 past situations where a non-financial company looked like ANONDITA MEDICARE LIMITED today on valuation, return on capital, debt, growth, price momentum, size and volatility.
- Over the following 12 months the middle half of them returned −40% to +7% vs the market, against −3% for all non-financial companies in the same months.
- The analogs' median sat below that base rate (gap −14.0%, 80% range −26.7% to −7.6%), but the matches cluster in only 6 distinct 12-month windows.
Where the 50 outcomes landed
Each dot is one past situation (hover or tap for details) · Solid dots are the closest matches, listed below · Shaded is the middle half of all companies in the same months · 2 beyond the range shown, drawn at the edge
50 past situations · 50 companies · 35 months · 2020–2025
The closest matches
| Company | When | P/E | ROCE | 12M mom. | Drawdown | Next 12 months |
|---|---|---|---|---|---|---|
| JSLL Health Services |
Jun 2025 | 66x | — | +98% | −10% | +39% |
| SAHANA Technology Services |
Nov 2024 | 68x | 55% | +157% | −18% | −36% |
| SAFARI Consumer Durables |
Oct 2023 | 78x | 37% | +123% | −8% | −23% |
| SBCL Non-Energy Minerals |
Jul 2023 | 51x | 38% | +151% | −2% | −38% |
| SHAREINDIA Finance |
May 2022 | 48x | 36% | +143% | −19% | 0% |
Show the other 3 matches
| Company | When | P/E | ROCE | 12M mom. | Drawdown | Next 12 months |
|---|---|---|---|---|---|---|
| BALAMINES Process Industries |
Sep 2021 | 62x | 35% | +460% | −9% | −30% |
| MIDHANI Non-Energy Minerals |
May 2020 | 29x | — | +46% | −20% | −45% |
| FAIRCHEMOR Process Industries |
Jan 2022 | 61x | 30% | +233% | −12% | −42% |
How reliable is this?
Matched on P/E, P/S, ROCE, debt/equity, interest cover, revenue growth, 12-month momentum, drawdown from 12-month high, size and volatility. Closest on: drawdown from 12-month high, P/E and 12-month momentum. Not used (unavailable for this company): operating margin. One match per company and at most 7 from any one month.
Independent periods: the matches fall in 6 distinct 12-month windows. Matches from nearby months share the same market conditions, so fewer windows means less evidence.
Monthly history (14 months)
| Month | P/E | Revenue (TTM) | ROE | ROCE | Debt / Equity |
|---|---|---|---|---|---|
| 2026-10 | 55.4x | ₹137 cr | 26.0% | 44.0% | 0.3x |
| 2026-09 | 61.6x | ₹137 cr | 26.4% | 44.0% | 0.3x |
| 2026-08 | 60.8x | ₹137 cr | 26.4% | 44.0% | 0.3x |
| 2026-07 | 61.5x | ₹137 cr | 26.4% | 44.0% | 0.3x |
| 2026-06 | 64.9x | ₹137 cr | 26.4% | 44.0% | 0.3x |
| 2026-05 | 93.2x | ₹77 cr | 43.2% | — | 0.7x |
| 2026-04 | 87.7x | ₹77 cr | 43.2% | — | 0.7x |
| 2026-03 | 57.8x | ₹77 cr | 43.2% | — | 0.7x |
| 2026-02 | 65.8x | ₹77 cr | 43.2% | — | 0.7x |
| 2026-01 | 83.6x | ₹77 cr | 43.2% | — | 0.7x |
| 2025-12 | 89.3x | ₹77 cr | 43.2% | — | 0.7x |
| 2025-11 | 56.7x | ₹77 cr | 43.2% | — | 0.7x |
| 2025-10 | 52.3x | ₹77 cr | 43.2% | — | 0.7x |
| 2025-09 | 31.1x | ₹77 cr | 43.2% | — | 0.7x |